KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $5.9 million.

  • Aurinia Pharmaceuticals' Share-based Compensation fell 2891.8% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year decrease of 5090.94%. This contributed to the annual value of $31.6 million for FY2024, which is 3026.86% down from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Share-based Compensation stood at $5.9 million, which was down 2891.8% from $5.4 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Share-based Compensation's 5-year high stood at $12.3 million during Q2 2023, with a 5-year trough of -$3.4 million in Q1 2025.
  • For the 5-year period, Aurinia Pharmaceuticals' Share-based Compensation averaged around $7.9 million, with its median value being $8.3 million (2024).
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Share-based Compensation surged by 12371.28% in 2021, and later tumbled by 15942.13% in 2025.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Share-based Compensation stood at $8.6 million in 2021, then fell by 19.53% to $6.9 million in 2022, then soared by 70.5% to $11.8 million in 2023, then dropped by 23.98% to $8.9 million in 2024, then tumbled by 33.84% to $5.9 million in 2025.
  • Its Share-based Compensation stands at $5.9 million for Q3 2025, versus $5.4 million for Q2 2025 and -$3.4 million for Q1 2025.